• Explore /
  • Poster
  • / Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study.

Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study.

Abstract Poster

Authors

null

Jing Huang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Jing Huang , Bo Zhang , Jialin Tang , Qing Chang , Rui Zhang , Chengyun Geng , Dawei Wu , Ling Qi , Xiangyong Gu , Binlei Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other IO-Related Topics

Clinical Trial Registration Number

NCT03866525

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3139)

DOI

10.1200/JCO.2020.38.15_suppl.3139

Abstract #

3139

Poster Bd #

203

Abstract Disclosures

Similar Posters

First Author: Soohyeon Lee

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang

First Author: Toshio Shimizu

First Author: Judy Sing-Zan Wang